newsfilter
← Latest News
GlobeNewswire·

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

  • Altimmune, Inc. management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.
  • A webcast of the event will be accessible via the Events section of the Altimmune website.
  • Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a dual-action investigational therapy targeting glucagon & GLP-1 receptors in a 1:1 ratio.
  • Pemvidutide is in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), & alcohol-associated liver disease (ALD).
  • Investor inquiries can be directed to Luis Sanay, Vice President of Investor Relations, via ir@altimmune.com.
  • Media inquiries should be directed to Real Chemistry at altimmune@realchemistry.com.